Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Medical Devices

Axogen, Inc. produces and distributes medical and surgical instruments. The Company offers devices and technology development for peripheral nerve reconstruction and regeneration. Axogen offers nerve graft, connectors, and soft tissue membrane.
Website: axogeninc.com



Growth: Good revenue growth rate 19.5%, there is acceleration compared to average historical growth rates 15.3%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +3.1%. On average the margin is improving steadily. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 80% of quarters (showing a gain of +$0.05 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 1.1% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 179.2% higher than minimum and 49.8% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 2.5x by EV / Sales multiple , the company can be 3.9% overvalued

Insiders: For the last 3 months insiders sold company shares on $0.5 mln (-0.083% of cap.)

Key Financials (Download financials)

Ticker: AXGN
Share price, USD:  (-0.9%)10.0803
year average price 13.90  


year start price 7.83 2024-06-13

min close price 6.81 2024-06-20

max close price 20.09 2025-02-25

current price 10.08 2025-06-12
Common stocks: 45 204 076

Dividend Yield:  0.0%
FCF Yield LTM: 1.1%
EV / LTM EBITDA: 84.1x
EV / Sales: 2.6x
Margin (EBITDA LTM / Revenue): 3.1%
Fundamental value created in LTM:
Market Cap ($m): 456
Net Debt ($m): 49
EV (Enterprise Value): 505
Price to Book: 4.6x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-05-08globenewswire.com

Axogen, Inc. Reports 2025 First Quarter Financial Results

2025-02-25globenewswire.com

Axogen, Inc. To Host Analyst & Investor Day on March 4th

2025-02-11globenewswire.com

Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025

2025-01-13zacks.com

AxoGen, Inc. (AXGN) Soars to 52-Week High, Time to Cash Out?

2025-01-13zacks.com

AxoGen (AXGN) Moves 18.2% Higher: Will This Strength Last?

2025-01-06seekingalpha.com

Axogen: Well Placed To Capitalize Growth At Higher Multiples

2024-12-19zacks.com

Is AxoGen (AXGN) Stock Outpacing Its Medical Peers This Year?

2024-11-28zacks.com

All You Need to Know About AxoGen (AXGN) Rating Upgrade to Buy

2024-11-09seekingalpha.com

Axogen, Inc (AXGN) Q3 2024 Earnings Call Transcript

2024-09-23zacks.com

First September Gains in 5 Years? Buy 3 Breakout Stocks Now
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol AXGN AXGN AXGN AXGN AXGN AXGN AXGN AXGN AXGN
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 805 928 805 928 805 928 805 928 805 928 805 928 805 928 805 928 805 928
fillingDate 2024-11-07 2024-08-08 2024-05-02 2024-03-05 2023-11-07 2023-08-08 2023-05-09 2023-03-14 2022-11-08
acceptedDate 2024-11-07 16:12:44 2024-08-08 16:10:38 2024-05-02 16:07:28 2024-03-05 16:27:20 2023-11-07 16:03:31 2023-08-08 16:29:35 2023-05-09 16:24:07 2023-03-14 16:38:39 2022-11-08 16:06:09
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 49M 48M 41M 43M 41M 38M 37M 36M 37M
costOfRevenue 12M 13M 9M 9M 8M 7M 7M 6M 6M
grossProfit 36M 35M 33M 34M 33M 31M 30M 30M 31M
grossProfitRatio 0.749 0.738 0.788 0.787 0.805 0.811 0.817 0.83 0.833
researchAndDevelopmentExpenses 7M 7M 7M 7M 7M 7M 7M 7M 7M
generalAndAdministrativeExpenses 11M 9M 10M 7M 9M 10M 9M 9M 9M
sellingAndMarketingExpenses 19M 20M 20M 22M 21M 21M 22M 20M 20M
sellingGeneralAndAdministrativeExpenses 30M 29M 30M 30M 30M 30M 31M 29M 29M
otherExpenses 0 1000 -107 000 -74 000 -6000 -277 000 -81 000 -133 000 0
operatingExpenses 37M 36M 37M 37M 37M 38M 37M 36M 36M
costAndExpenses 49M 48M 46M 46M 45M 45M 44M 42M 42M
interestIncome 0 0 0 336 000 367 000 235 000 0 0 0
interestExpense 2M 2M 2M 2M 827 000 148 000 16 000 -40 000 61 000
depreciationAndAmortization 2M 2M 2M 2M 1M 1M 1M 1M 1M
ebitda 2M 2M -3M -1M -3M -6M -6M -5M -4M
ebitdaratio 0.041 0.034 -0.064 -0.031 -0.064 -0.161 -0.169 -0.126 -0.098
operatingIncome -316 000 -428 000 -5M -3M -4M -7M -7M -6M -5M
operatingIncomeRatio -0.006 -0.009 -0.11 -0.074 -0.098 -0.181 -0.2 -0.155 -0.131
totalOtherIncomeExpensesNet -2M -1M -2M -699 000 763 000 390 000 267 000 193 000 537 000
incomeBeforeTax -2M -2M -7M -4M -4M -7M -7M -5M -4M
incomeBeforeTaxRatio -0.038 -0.04 -0.16 -0.091 -0.099 -0.175 -0.193 -0.15 -0.117
incomeTaxExpense 0 0 2M -328 000 821 000 -129 000 -364 000 -286 000 -655 000
netIncome -2M -2M -7M -4M -4M -7M -7M -5M -4M
netIncomeRatio -0.038 -0.04 -0.16 -0.091 -0.099 -0.175 -0.183 -0.142 -0.099
eps -0.042 -0.044 -0.15 -0.09 -0.095 -0.16 -0.16 -0.13 -0.087
epsdiluted -0.042 -0.044 -0.15 -0.09 -0.095 -0.16 -0.16 -0.13 -0.087
weightedAverageShsOut 44M 44M 43M 43M 43M 43M 43M 40M 42M
weightedAverageShsOutDil 44M 44M 43M 43M 43M 43M 43M 40M 42M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol AXGN AXGN AXGN AXGN AXGN AXGN AXGN AXGN AXGN
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 805 928 805 928 805 928 805 928 805 928 805 928 805 928 805 928 805 928
fillingDate 2024-11-07 2024-08-08 2024-05-02 2024-03-05 2023-11-07 2023-08-08 2023-05-09 2023-03-14 2022-11-08
acceptedDate 2024-11-07 16:12:44 2024-08-08 16:10:38 2024-05-02 16:07:28 2024-03-05 16:27:20 2023-11-07 16:03:31 2023-08-08 16:29:35 2023-05-09 16:24:07 2023-03-14 16:38:39 2022-11-08 16:06:09
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 19M 25M 22M 37M 31M 23M 8M 15M 14M
shortTermInvestments 6M 2M 2M 0 1M 11M 30M 34M 39M
cashAndShortTermInvestments 25M 27M 24M 37M 33M 35M 38M 49M 53M
netReceivables 25M 25M 24M 25M 23M 22M 22M 22M 21M
inventory 29M 28M 28M 23M 23M 21M 20M 19M 19M
otherCurrentAssets 8M 12M 3M 3M 3M 3M 2M 2M 3M
totalCurrentAssets 86M 82M 79M 88M 87M 86M 89M 98M 102M
propertyPlantEquipmentNet 101M 102M 103M 104M 103M 101M 97M 94M 90M
goodwill 0 0 0 0 0 0 0 0 0
intangibleAssets 5M 5M 5M 5M 4M 4M 4M 4M 3M
goodwillAndIntangibleAssets 5M 5M 5M 5M 4M 4M 4M 4M 3M
longTermInvestments 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 0 -1 0 0 -107M -105M 0 0 0
totalNonCurrentAssets 106M 107M 108M 109M 107M 105M 101M 97M 93M
otherAssets 0 1 0 0 0 0 0 0 0
totalAssets 192M 189M 187M 197M 195M 192M 189M 195M 196M
accountPayables 0 22M 21M 29M 26M 23M 0 9M 0
shortTermDebt 2M 4M 2M 2M 1M 1M 1M 1M 2M
taxPayables 0 0 0 0 0 0 0 0 0
deferredRevenue 0 -22M -2M -19M -26M -23M 0 0 0
otherCurrentLiabilities 21M -2M 2M 19M 26M 23M 20M 13M 22M
totalCurrentLiabilities 23M 23M 23M 30M 27M 24M 21M 24M 24M
longTermDebt 67M 67M 47M 47M 66M 66M 66M 66M 66M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 3M 3M 24M 24M 4M 4M 5M 5M 69M
totalNonCurrentLiabilities 70M 70M 70M 71M 70M 71M 71M 71M 71M
otherLiabilities 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 22M 22M 21M 21M 21M 21M 21M 22M 22M
totalLiabilities 93M 93M 93M 101M 97M 94M 92M 94M 94M
preferredStock 0 0 0 1 0 0 0 0 0
commonStock 440 000 438 000 437 000 431 000 430 000 430 000 428 000 424 000 423 000
retainedEarnings -292M -290M -288M -281M -277M -273M -267M -260M -254M
accumulatedOtherComprehensiveIncomeLoss 0 0 0 0 0 0 0 0 0
othertotalStockholdersEquity 391M 385M 381M 377M 375M 370M 364M 360M 355M
totalStockholdersEquity 99M 96M 93M 96M 98M 97M 98M 101M 101M
totalEquity 99M 96M 93M 96M 98M 97M 98M 101M 101M
totalLiabilitiesAndStockholdersEquity 192M 189M 187M 197M 195M 192M 189M 195M 196M
minorityInterest 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 192M 189M 187M 197M 195M 192M 189M 195M 196M
totalInvestments 6M 2M 2M 0 1M 11M 30M 34M 39M
totalDebt 69M 69M 69M 69M 67M 67M 67M 67M 68M
netDebt 50M 44M 47M 32M 36M 44M 59M 52M 53M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol AXGN AXGN AXGN AXGN AXGN AXGN AXGN AXGN AXGN
reportedCurrency USD USD USD USD USD USD USD USD USD
cik 805 928 805 928 805 928 805 928 805 928 805 928 805 928 805 928 805 928
fillingDate 2024-11-07 2024-08-08 2024-05-02 2024-03-05 2023-11-07 2023-08-08 2023-05-09 2023-03-14 2022-11-08
acceptedDate 2024-11-07 16:12:44 2024-08-08 16:10:38 2024-05-02 16:07:28 2024-03-05 16:27:20 2023-11-07 16:03:31 2023-08-08 16:29:35 2023-05-09 16:24:07 2023-03-14 16:38:39 2022-11-08 16:06:09
calendarYear 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -2M -2M -7M -4M -4M -7M -7M -5M -4M
depreciationAndAmortization 2M 2M 2M 2M 1M 1M 1M 1M 1M
deferredIncomeTax 0 0 0 -147 000 30 000 117 000 0 0 0
stockBasedCompensation 5M 4M 4M 1M 5M 5M 3M 4M 4M
changeInWorkingCapital 14M -2M -12M 971 000 -694 000 174 000 -5M 957 000 -2M
accountsReceivables 448 000 -1M 681 000 -2M -1M 475 000 175 000 -944 000 -976 000
inventory 978 000 -2M -5M -99 000 -3M -2M -2M 148 000 -346 000
accountsPayables -548 000 714 000 -7M 3M 4M 2M -2M 0 0
otherWorkingCapital 13M 990 000 -623 000 -502 000 -248 000 -355 000 -1M 2M -295 000
otherNonCashItems -15M 13M 20M -322 000 224 000 223 000 291 000 496 000 123 000
netCashProvidedByOperatingActivities 4M 4M -12M -211 000 2M 292 000 -7M 1M -689 000
investmentsInPropertyPlantAndEquipment 142 000 -1M -1M -2M -4M -5M -5M -7M -5M
acquisitionsNet 0 0 0 -253 000 0 0 253 000 0 0
purchasesOfInvestments -4M -1000 -2M 10M 0 0 -10M -15M -19M
salesMaturitiesOfInvestments 0 0 0 2M 10M 19M 14M 20M 26M
otherInvestingActivites -1M -323 000 -2M -10M 10M 0 -253 000 0 0
netCashUsedForInvestingActivites -5M -1M -3M -277 000 6M 14M -786 000 -1M 3M
debtRepayment -2000 -1000 -3000 -3000 -5000 -11 000 -1000 -3000 -8000
commonStockIssued -752 000 545 000 207 000 421 000 0 909 000 634 000 0 0
commonStockRepurchased 0 0 0 0 0 0 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites 574 000 545 000 207 000 2M 10000 0 0 816 000 223 000
netCashUsedProvidedByFinancingActivities 572 000 544 000 204 000 418 000 5000 898 000 633 000 813 000 215 000
effectOfForexChangesOnCash 0 0 0 6M 0 0 0 0 0
netChangeInCash -527 000 3M -15M -70 000 8M 16M -8M 966 000 2M
cashAtEndOfPeriod 25M 25M 22M 37M 37M 29M 14M 22M 21M
cashAtBeginningOfPeriod 25M 22M 37M 37M 29M 14M 22M 21M 18M
operatingCashFlow 4M 4M -12M -211 000 2M 292 000 -7M 1M -689 000
capitalExpenditure 142 000 -1M -1M -2M -4M -5M -5M -7M -5M
freeCashFlow 4M 3M -14M -2M -2M -4M -12M -5M -5M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link

Earning call transcript

2024 q3
2024-11-09 ET (fiscal 2024 q3)
2024 q2
2024-08-08 ET (fiscal 2024 q2)
2024 q1
2024-05-05 ET (fiscal 2024 q1)
2023 q4
2024-03-05 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-07 ET (fiscal 2023 q2)
2023 q1
2023-05-09 ET (fiscal 2023 q1)
2022 q4
2023-03-14 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-06 ET (fiscal 2022 q2)
2022 q1
2022-05-07 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2024-11-07 12:00 ET
Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update
2024-10-24 11:00 ET
Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024
2024-09-06 11:00 ET
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
2024-09-03 11:00 ET
Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)
2024-08-08 11:05 ET
Axogen, Inc. Announces New Leadership Appointments
2024-08-08 11:00 ET
Axogen, Inc. Reports Second Quarter 2024 Financial Results
2024-07-23 11:00 ET
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
2024-07-01 11:00 ET
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
2024-06-24 11:00 ET
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
2024-05-28 20:30 ET
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
2024-05-16 11:00 ET
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
2024-05-14 11:00 ET
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
2024-05-02 11:00 ET
Axogen, Inc Reports First Quarter 2024 Financial Results
2024-04-29 20:50 ET
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
2024-04-16 11:00 ET
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
2024-03-05 12:00 ET
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
2024-02-13 21:30 ET
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
2024-02-02 21:15 ET
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
2024-01-18 22:00 ET
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
2024-01-04 21:45 ET
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2023
2024-01-04 21:40 ET
Axogen Announces Plan for Leadership Transition with CEO Karen Zaderej to Retire from Company by January 2025
2024-01-04 21:35 ET
Axogen Announces Promotions on Research and Development Team
2023-12-26 21:15 ET
Axogen, Inc. Appoints Kathy Weiler to its Board of Directors
2023-12-06 12:00 ET
Axogen Announces Transition of Finance Team Leadership
2023-12-01 22:00 ET
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2023-11-20 12:00 ET
Axogen, Inc. to Participate at the Piper Sandler 35th Annual Healthcare Conference
2023-11-07 12:00 ET
Axogen, Inc. Reports 2023 Third Quarter Financial Results
2023-10-18 11:00 ET
Axogen, Inc. to Report Third Quarter 2023 Financial Results and Host Conference Call on November 7, 2023
2023-09-05 11:00 ET
Axogen, Inc. Announces Full Launch of Axoguard HA+ Nerve Protector™
2023-08-31 11:00 ET
Axogen to Participate at Upcoming Investor Conferences
2023-08-21 11:00 ET
Axogen, Inc. Begins Processing Avance® Nerve Graft at New State-of-the-Art Facility in Dayton, Ohio
2023-08-07 20:01 ET
Axogen, Inc. Reports 2023 Second Quarter Financial Results
2023-07-27 11:00 ET
Axogen to Participate at Canaccord Genuity’s 43rd Annual Growth Conference
2023-07-26 11:00 ET
Axogen, Inc. to report second quarter 2023 financial results and host conference call on August 7, 2023
2023-05-24 11:00 ET
Axogen to Participate at Jefferies Healthcare Conference
2023-05-12 11:00 ET
Axogen to Participate at JMP Securities Life Sciences Conference
2023-05-09 11:00 ET
Axogen, Inc. Reports 2023 First Quarter Financial Results
2023-04-18 20:05 ET
Axogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023
2023-03-14 11:00 ET
Axogen, Inc Reports 2022 Fourth Quarter and Full-Year Financial Results
2023-03-06 12:00 ET
Axogen, Inc. Appoints Marc Began as Executive Vice President and General Counsel
2023-03-02 21:00 ET
Axogen, Inc. to report fourth quarter 2022 financial results and host conference call on March 14, 2023
2023-02-13 12:00 ET
Axogen, Inc. Appoints Jens Schroeder Kemp as Chief Marketing Officer
2023-01-09 12:00 ET
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2022
2023-01-05 12:00 ET
Axogen Announces Independent Publication of Comparative Nerve Gap Repair Meta-Analysis of 35 peer-reviewed studies of Allograft, Autograft, and Conduits
2023-01-04 12:00 ET
Axogen to Participate at J.P. Morgan 41st Annual Healthcare Conference
2022-12-19 12:00 ET
Axogen Patient to Ride the 2023 Donate Life Rose Parade® Float Supporting awareness of organ and tissue donation
2022-11-08 12:00 ET
Axogen, Inc Reports 2022 Third Quarter Financial Results
2022-11-03 20:00 ET
Axogen to Participate at Upcoming Investor Conferences
2022-10-31 11:00 ET
Axogen, Inc. announces the appointment of Adrian Tyndall, M.D. MPH, FACEP to its Board of Directors and the retirement of founding Director Mark Gold, M.D.
2022-10-20 11:00 ET
Axogen, Inc. to report third quarter 2022 financial results and host conference call on November 8, 2022
2022-09-22 11:00 ET
Axogen to Participate in the 77th Annual Meeting of the American Society for Surgery of the Hand
2022-08-03 20:01 ET
Axogen, Inc Reports 2022 Second Quarter Financial Results
2022-07-29 11:00 ET
Axogen, Inc. to present at Canaccord Genuity's 42nd Annual Growth Conference
2022-07-18 20:00 ET
Axogen, Inc. Announces Organizational Updates, Preliminary Second Quarter Revenue and Reaffirms Full-Year 2022 Financial Guidance
2022-07-11 11:00 ET
Axogen, Inc. Appoints William Burke to Board of Directors
2022-05-18 11:00 ET
Axogen, Inc. to present at the Jefferies Virtual Healthcare Conference and the JMP Securities Life Sciences Conference
2022-05-04 20:05 ET
Axogen, Inc Reports 2022 First Quarter Financial Results
2022-05-04 20:01 ET
Axogen, Inc. Announces Positive Topline Results from Phase 3 RECON(SM) Study for Avance® Nerve Graft
2022-04-13 11:00 ET
Axogen, Inc. to Report First Quarter 2022 Financial Results and Host Conference Call on May 4, 2022
2022-03-17 11:00 ET
Axogen, Inc. publishes inaugural ESG Report
2022-02-22 21:34 ET
Axogen, Inc. Reports 2021 Fourth Quarter and Full-Year Financial Results
2022-02-03 12:00 ET
Axogen to Participate at Upcoming Investor Conferences
2022-02-02 12:00 ET
Axogen, Inc. to Report Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call on February 22, 2022
2022-01-10 12:00 ET
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2021
2022-01-04 12:00 ET
Axogen to Participate at AAHS ASPN ASRM 2022 Annual Meetings
2021-12-15 12:00 ET
Axogen sponsors 2022 Donate Life Rose Parade® Float to help raise awareness of organ and tissue donation
2021-11-10 12:00 ET
Axogen, Inc. to Participate at Canaccord Genuity Virtual MedTech, Diagnostics and Digital Health & Services Forum
2021-11-04 11:00 ET
Axogen, Inc. to Participate at Jefferies London Healthcare Conference
2021-11-03 20:01 ET
Axogen, Inc. Reports 2021 Third Quarter Financial Results
2021-10-13 11:00 ET
Axogen, Inc. to Report Third Quarter Financial Results and Host Conference Call on November 3, 2021
2021-09-22 11:00 ET
Axogen to Participate in the 76th Annual Meeting of the American Society for Surgery of the Hand
2021-09-01 11:00 ET
Axogen RECON(SM) Clinical Study Completes Subject Follow-up
2021-08-04 20:01 ET
Axogen, Inc. Reports 2021 Second Quarter Financial Results
2021-07-22 11:00 ET
Axogen, Inc. to Present at the Canaccord Genuity 41st Annual Growth Conference
2021-07-19 20:01 ET
Axogen, Inc. Appoints John H. Johnson to Board of Directors
2021-07-14 11:00 ET
Axogen, Inc. to Report Second Quarter Financial Results and Host Conference Call on August 4, 2021
2021-05-18 11:00 ET
Axogen, Inc. to present at the Jefferies Virtual Healthcare Conference and the JMP Securities Life Sciences Conference
2021-05-06 11:00 ET
Axogen, Inc. to Present at the Canaccord Genuity Musculoskeletal Conference
2021-05-05 20:00 ET
Axogen, Inc. Reports 2021 First Quarter Financial Results
2021-04-14 11:00 ET
Axogen, Inc. to Report First Quarter Financial Results and Host Conference Call on May 5, 2021
2021-03-01 21:01 ET
Axogen, Inc. Promotes Peter J. Mariani to Executive Vice President and Chief Financial Officer
2021-02-22 21:01 ET
Axogen, Inc. Reports 2020 Fourth Quarter and Full-Year Financial Results
2021-02-18 12:00 ET
Axogen Sponsored REPOSE℠ Study Completes Pilot Phase Analysis
2021-02-04 12:00 ET
Axogen, Inc. to Participate at Upcoming February Investor Conferences
2021-02-01 12:00 ET
Axogen, Inc. to Report Fourth Quarter and Full-Year 2020 Financial Results and Host Conference Call on February 22, 2021
2021-01-11 12:00 ET
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2020
2021-01-05 12:00 ET
Axogen to Participate at AAHS ASPN ASRM 2021 Virtual Annual Meetings
2020-12-23 12:00 ET
Axogen Sponsors Donate Life at 2021 Virtual Rose Parade Celebration
2020-11-04 12:00 ET
Axogen, Inc. to Participate at Jefferies Virtual London Healthcare Conference and Canaccord Genuity Virtual MedTech & Diagnostics Forum
2020-10-29 20:01 ET
Axogen, Inc. Reports Third Quarter 2020 Financial Results
2020-10-08 11:00 ET
Axogen, Inc. to Report Third Quarter 2020 Financial Results and Host Conference Call on October 29, 2020
2020-09-30 20:01 ET
Axogen, Inc. Appoints Paul G. Thomas to Board of Directors
2020-09-25 11:00 ET
Axogen, Inc. to Present at the JMP Securities MedTech Bio Summit
2020-09-24 11:00 ET
Axogen to Participate in the 75th Annual American Society for Surgery of the Hand Meeting
2020-08-31 11:00 ET
Axogen, Inc. to Present at the Cantor Virtual Global Healthcare Conference
2020-08-05 20:01 ET
Axogen, Inc. Reports Second Quarter 2020 Financial Results
2020-07-29 11:00 ET
Axogen, Inc. to Present at the Canaccord Genuity 40th Annual Growth Conference
2020-07-22 11:00 ET
Axogen RECON Clinical Study Completes Target Enrollment of 220 Subjects
2020-07-15 11:00 ET
Axogen, Inc. to Report Second Quarter 2020 Financial Results and Host Conference Call on August 5, 2020
2020-07-01 11:00 ET
Axogen Announces New Seven-Year Financing Agreement with Oberland Capital and Provides Preliminary Second Quarter Revenue Estimate
2020-06-01 11:00 ET
Axogen, Inc. Announces Planned Retirement of Greg Freitag and Appoints Brad Ottinger as General Counsel and Chief Compliance Officer
2020-05-20 11:00 ET
Axogen, Inc. to Present at the Jefferies Virtual Healthcare Conference
2020-05-06 20:01 ET
Axogen, Inc. Reports First Quarter 2020 Financial Results
2020-04-23 11:00 ET
Axogen, Inc. Reports Preliminary Revenue for the First Quarter 2020, Provides Business Update in Response to COVID-19 Pandemic, and Announces Dismissal of Class Action Lawsuit
2020-04-15 11:00 ET
Axogen, Inc. to Report First Quarter 2020 Financial Results and Host Conference Call on May 6, 2020
2020-03-02 12:00 ET
Axogen, Inc. to Participate at Upcoming Investor Conferences
2020-02-24 21:01 ET
Axogen, Inc. Reports Fourth Quarter and Full-Year 2019 Financial Results
2020-02-05 12:00 ET
Axogen, Inc. to Present at the Leerink Partners 9th Annual Global Healthcare Conference
2020-02-03 12:00 ET
Axogen, Inc. to Report Fourth Quarter and Full-Year 2019 Financial Results and Host Conference Call on February 24, 2020
2020-01-13 12:00 ET
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2019 and Provides 2020 Annual Guidance
2020-01-08 12:00 ET
Axogen Sponsored RANGER® Registry Reaches 2,000 Nerve Repair Enrollment Milestone
2020-01-02 21:01 ET
Axogen to Participate at AAHS ASPN ASRM 2020 Annual Meetings
2020-01-02 12:00 ET
Axogen, Inc. to Participate at JP Morgan 38th Annual Healthcare Conference
2019-12-18 12:00 ET
Axogen awarded research grant from the Advanced Regenerative Manufacturing Institute
2019-12-04 12:00 ET
Avance® Nerve Graft Recipient Selected to Ride on Donate Life Rose Parade® Float
2019-11-21 12:00 ET
Axogen, Inc. to Participate at Piper Jaffray 31st Annual Healthcare Conference
2019-11-11 12:00 ET
Axogen, Inc. to Participate at Jefferies London Healthcare Conference
2019-11-06 21:04 ET
Axogen, Inc. Reports 2019 Third Quarter Financial Results
2019-10-23 11:00 ET
Axogen, Inc. to Report Third Quarter 2019 Financial Results and Host Conference Call on November 6, 2019
2019-10-03 17:40 ET
Scott+Scott Attorneys at Law LLP Investigating Axogen, Inc.'s Directors and Officers for Breach of Fiduciary Duties - AXGN
2019-09-19 11:00 ET
Axogen, Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
2019-07-26 11:50 ET
(AXGN) Alert: Johnson Fistel, LLP Announces Investigation of AxoGen, Inc.; Long Term Investors Encouraged to Contact Firm

SEC forms

Show financial reports only

SEC form 10
2025-05-08 20:38 ET
Axogen published news for 2025 q1
SEC form 8
2025-05-08 11:10 ET
Axogen published news for 2025 q1
SEC form 8
2025-05-08 11:10 ET
Axogen reported for 2025 q1
SEC form 8
2025-05-08 11:10 ET
Axogen published news for 2025 q1
SEC form 8
2025-05-08 11:10 ET
Axogen published news for 2025 q1
SEC form 8
2025-05-08 11:10 ET
Axogen published news for 2025 q1
SEC form 10
2025-05-08 00:00 ET
Axogen published news for 2025 q1
SEC form 10
2025-02-26 00:00 ET
Axogen published news for 2024 q4
SEC form 8
2025-02-25 00:00 ET
Axogen published news for 2024 q4
SEC form 8
2025-02-25 00:00 ET
Axogen reported for 2024 q4
SEC form 8
2025-02-25 00:00 ET
Axogen published news for 2024 q4
SEC form 8
2025-01-10 00:00 ET
Axogen published news for 2024 q4
SEC form 8
2025-01-10 00:00 ET
Axogen published news for 2024 q4
SEC form 10
2024-11-07 16:12 ET
Axogen published news for 2024 q3
SEC form 8
2024-11-07 07:08 ET
Axogen published news for 2024 q3
SEC form 8
2024-11-07 07:08 ET
Axogen published news for 2024 q3
SEC form 8
2024-11-07 07:08 ET
Axogen published news for 2024 q3
SEC form 10
2024-08-08 16:10 ET
Axogen published news for 2024 q2
SEC form 8
2024-08-08 07:14 ET
Axogen published news for 2024 q2
SEC form 8
2024-08-08 07:14 ET
Axogen reported for 2024 q2
SEC form 8
2024-08-08 07:14 ET
Axogen published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Axogen published news for 2024 q2
SEC form 10
2024-05-02 16:07 ET
Axogen published news for 2024 q1
SEC form 8
2024-05-02 07:00 ET
Axogen published news for 2024 q1
SEC form 8
2024-05-02 07:00 ET
Axogen reported for 2024 q1
SEC form 8
2024-05-02 07:00 ET
Axogen published news for 2024 q1
SEC form 10
2024-05-02 00:00 ET
Axogen published news for 2024 q1
SEC form 10
2024-03-05 16:27 ET
Axogen published news for 2023 q4
SEC form 8
2024-03-05 07:16 ET
Axogen reported for 2023 q4
SEC form 8
2024-03-05 07:16 ET
Axogen published news for 2023 q4
SEC form 10
2024-03-05 00:00 ET
Axogen published news for 2023 q4
SEC form 8
2024-01-04 00:00 ET
Axogen published news for 2023 q4
SEC form 8
2024-01-04 00:00 ET
Axogen published news for 2023 q4
SEC form 8
2024-01-04 00:00 ET
Axogen published news for 2023 q4
SEC form 8
2024-01-04 00:00 ET
Axogen published news for 2023 q4
SEC form 10
2023-11-07 16:03 ET
Axogen published news for 2023 q3
SEC form 8
2023-11-07 07:13 ET
Axogen reported for 2023 q3
SEC form 10
2023-11-07 00:00 ET
Axogen published news for 2023 q3
SEC form 10
2023-08-08 16:29 ET
Axogen published news for 2023 q2
SEC form 10
2023-08-08 00:00 ET
Axogen published news for 2023 q2
SEC form 6
2023-08-07 16:08 ET
Axogen reported for 2023 q2
SEC form 8
2023-08-07 00:00 ET
Axogen published news for 2023 q2
SEC form 6
2023-07-07 16:32 ET
Axogen published news for 2023 q2
SEC form 6
2023-06-30 16:05 ET
Axogen published news for 2023 q1
SEC form 6
2023-06-21 16:28 ET
Axogen published news for 2023 q1
SEC form 8
2023-05-09 00:00 ET
Axogen published news for 2023 q1
SEC form 10
2023-05-09 00:00 ET
Axogen published news for 2023 q1
SEC form 8
2023-03-14 00:00 ET
Axogen reported for 2022 q4
SEC form 10
2023-03-14 00:00 ET
Axogen reported for 2022 q4
SEC form 8
2023-01-09 00:00 ET
Axogen published news for 2022 q4
SEC form 10
2022-11-08 00:00 ET
Axogen reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Axogen reported for 2022 q3
SEC form 10
2022-08-05 00:00 ET
Axogen reported for 2022 q2
SEC form 8
2022-08-03 00:00 ET
Axogen reported for 2022 q2
SEC form 8
2022-07-18 00:00 ET
Axogen published news for 2022 q2
SEC form 10
2022-05-05 00:00 ET
Axogen reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
Axogen reported for 2022 q1
SEC form 10
2022-02-25 00:00 ET
Axogen published news for 2021 q4
SEC form 8
2022-02-22 00:00 ET
Axogen published news for 2021 q4
SEC form 8
2022-01-10 00:00 ET
Axogen published news for 2021 q4
SEC form 10
2021-11-04 00:00 ET
Axogen published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
Axogen published news for 2021 q3
SEC form 10
2021-08-05 00:00 ET
Axogen published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
Axogen published news for 2021 q2
SEC form 10
2021-05-06 00:00 ET
Axogen published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
Axogen published news for 2021 q1